The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
